Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
August 15 2024 - 8:05AM
Business Wire
Company-Sponsored Industry Symposium To Be Held
at the ERS Congress
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage
biopharmaceutical company focused on rare respiratory diseases,
today announced the acceptance of an abstract for poster
presentation at the European Respiratory Society (ERS) Congress
2024, taking place September 7-11, 2024, in Vienna, Austria. The
Company is also sponsoring an Industry Symposium at the Congress.
Details are as follows:
Accepted Abstract Title: “Inhaled
Molgramostim Improves Pulmonary Gas Exchange and Respiratory
Health-Related Quality of Life (HRQoL) in Patients with Autoimmune
Pulmonary Alveolar Proteinosis (aPAP): Results from IMPALA-2”
Poster Session PS-29: Deep in Clinical Dilemmas of Non-Idiopathic
Interstitial Lung Diseases Date and Time: September 8, 2024,
12:30-14:00 CET
Company-Sponsored Symposium Title:
“Pulmonary Alveolar Proteinosis: Pathophysiology, Diagnosis, and
Management” Location: ERS Congress Industry Theater Date and Time:
September 8, 2024, 17:30 – 19:00 CET Speakers: Cormac McCarthy,
M.D., Ph.D., FRCPI, Elisabeth Bendstrup, M.D., Ph.D., and Francesco
Bonella, M.D., Ph.D.
About aPAP
Autoimmune PAP is a rare lung disease characterized by the
abnormal build-up of surfactant in the alveoli (or air sacs) of the
lungs. Surfactant consists of proteins and lipids and is an
important physiological substance that lines the inside of the
alveoli to prevent the alveoli from collapsing. In a healthy lung,
the old and inactivated surfactant is cleared and digested by
immune cells called alveolar macrophages. Alveolar macrophages need
to be stimulated by granulocyte-macrophage colony-stimulating
factor (GM-CSF) to function properly in clearing surfactant, but in
autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF,
rendering the macrophages unable to adequately clear surfactant.
The resulting excess surfactant accumulates in the alveoli,
creating a barrier to gas exchange, and manifesting clinically as
shortness of breath, often with cough and frequent fatigue.
Patients may also experience episodes of fever, chest pain, or
coughing up blood, especially if secondary lung infection develops.
In the long-term, the disease can lead to serious complications,
including lung fibrosis and the need for a lung transplant.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, molgramostim nebulizer
solution, is an inhaled granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary
alveolar proteinosis (aPAP). Molgramostim is delivered via an
investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our
management team has significant experience in rare respiratory
diseases and pulmonary medicine, identifying unmet needs, and
effectively advancing product candidates to approval and
commercialization. More information can be found at
www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma,
LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
Forward-Looking Statements
Savara cautions you that statements in this press release that
are not a description of historical fact are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements may be identified by
the use of words referencing future events or circumstances such as
“expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,”
among others. Savara may not actually achieve any of the matters
referred to in such forward-looking statements, and you should not
place undue reliance on these forward-looking statements. These
forward-looking statements are based upon Savara’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, the risks
associated with our ability to successfully develop, obtain
regulatory approval for, and commercialize molgramostim for aPAP;
the risks and uncertainties related to the impact of widespread
health concerns or changing economic or geopolitical conditions;
the ability to project future cash utilization and reserves needed
for contingent future liabilities and business operations; the
availability of sufficient resources for Savara’s operations and to
conduct or continue planned clinical development programs; and the
timing and ability of Savara to raise additional capital as needed
to fund continued operations. All forward-looking statements are
expressly qualified in their entirety by these cautionary
statements. For a detailed description of our risks and
uncertainties, you are encouraged to review our documents filed
with the SEC including our recent filings on Form 8-K, Form 10-K
and Form 10-Q. You are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date on
which they were made. Savara undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made, except as may be
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240815629806/en/
Savara Inc. IR & PR Anne Erickson
(anne.erickson@savarapharma.com) (512) 851-1366
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Aug 2023 to Aug 2024